$10.66
Value $710M
BVS and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$10.66
Value $710M
$147.76
Value $365B
Bioventus (BVS) has a market value of $710M and Merck & Company (MRK) $365B. Over the last year, with dividends, BVS moved +39.3% and MRK +66.3%. Dividend yield: BVS none, MRK 2.30%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
BVS$710M
MRK$365B
MRK is 514 times BVS
Revenue, 12 months
BVS$586M
MRK$67.4B
MRK is 115 times BVS
Net income, 12 months
BVS$57M
MRK$2.5B
MRK is 43 times BVS
Operating margin
BVS9.7%
MRK–
ROIC
BVS9.4%
MRK3.9%
5.5 points apart
P/E
BVS–
MRK148.9
Dividend yield
BVS0.0%
MRK2.3%
2.3 points apart
5-year return
BVS-32.7%
MRK+104.9%
137.6 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
BVS-32.7%
MRK+104.9%
| Period | BVSWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +39.3%Price +39.3% | +66.3%Price +61.6% |
| 3 years since November 13, 2023 | +188.1%+42.3% a yearPrice +188.1% | +58.0%+16.5% a yearPrice +44.2% |
| 5 years since November 12, 2021 | -32.7%-7.6% a yearPrice -32.7% | +104.9%+15.4% a yearPrice +75.9% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
BVSBioventusMRKMerck & Company
| Price | $10.66 | $147.76 |
|---|---|---|
| Market value | $710M | $365B |
| Enterprise value (EV) | $918M | $409B |
| P/E | – | 148.9 |
| P/E, 5-year median | – | 14.8 |
| P/B | 3.0 | 8.1 |
| EV/EBIT | 16.2 | 86.0 |
| Free cash flow yield | 12.0% | 4.0% |
| Revenue, 12 months | $586M | $67.4B |
|---|---|---|
| Net income, 12 months | $57M | $2.5B |
| Free cash flow, 12 months | $85M | $14.7B |
| Earnings per share, 12 months | $0.80 | $0.98 |
| Revenue growth, year on year | -0.9% | 1.3% |
| Revenue growth a year, past | +12.1%over 5 years | +9.4%over 5 years |
| EPS growth a year, past | – | +21.2%over 5 years |
| Gross margin | 68.7% | 71.8% |
|---|---|---|
| Operating margin | 9.7% | – |
| Net margin | 9.8% | 3.6% |
| ROIC | 9.4% | 3.9% |
| ROE | 28.4% | 5.2% |
| Cash | $31M | $9.7B |
|---|---|---|
| Total debt | $244M | $53.8B |
| Net debt / EBITDA | 2.0 | 5.7 |
| Interest cover | – | 2.4× |
| Dividend yield | – | 2.3% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | – | 1.4% |
| Shareholder yield | – | 3.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($365B) is about 514.4 times Bioventus ($710M), at today's prices.
Since November 12, 2021, BVS's price moved -32.7% and MRK's +75.9%. With dividends: BVS -32.7% (-7.6% a year), MRK +104.9% (+15.4% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Bioventus and 2.30% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
Over the last twelve months, the net margin was 9.8% for Bioventus and 3.6% for Merck & Company, and the operating margin 9.7% and –. Revenue was $586M and $67.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.